The estimated Net Worth of Christopher Bowden is at least 8.55 百万$ dollars as of 18 June 2021. Christopher Bowden owns over 48,493 units of Agios Pharmaceuticals Inc stock worth over 2,834,954$ and over the last 10 years he sold AGIO stock worth over 2,485,871$. In addition, he makes 3,227,210$ as Chief Medical Officer at Agios Pharmaceuticals Inc.
Christopher has made over 27 trades of the Agios Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 48,493 units of AGIO stock worth 2,424,165$ on 18 June 2021.
The largest trade he's ever made was selling 49,638 units of Agios Pharmaceuticals Inc stock on 4 February 2020 worth over 2,485,871$. On average, Christopher trades about 5,689 units every 53 days since 2014. As of 18 June 2021 he still owns at least 63,980 units of Agios Pharmaceuticals Inc stock.
You can see the complete history of Christopher Bowden stock trades at the bottom of the page.
Dr. Christopher J. Bowden M.D. serves as Chief Medical Officer of the Company. He joined Agios as chief medical officer in May 2014. He has more than 19 years of experience in clinical drug development, including the approval of several cancer medicines. Prior to joining Agios, Dr. Bowden was vice president product development oncology, franchise lead (Signaling Group) at Genentech. During Dr. Bowden’s eight years at Genentech, he was responsible for the successful development of a number of novel targeted oncology medicines, including Zelboraf® for patients with BRAF V600E positive melanoma and Tarceva® for patients with EGFr activating mutation positive, non-small cell lung cancer. From 2003 to 2006, Dr. Bowden was the executive director for EMEA (Europe, Middle East, Africa) regions for BMS. In this role, he led medical affairs strategies for cancer, immunology and pain medicines. Earlier, Dr. Bowden held positions of increasing responsibility in oncology clinical development, Phases I-III at Pharmacia Corporation and Janssen Pharmaceutical, Inc., each of which is a pharmaceutical company. Prior to his industry experience, Dr. Bowden was on the oncology faculty at the University of Virginia Health Science Center where he participated in numerous industry and cooperative group trials. Dr. Bowden received his M.D. from Hahnemann University School of Medicine followed by internal medicine training at Roger Williams Medical Center and the Providence VA Medical Center, Rhode Island. He completed his medical oncology fellowship at the National Cancer Institute Medicine Branch. Dr. Bowden is board certified in internal medicine and medical oncology.
As the Chief Medical Officer of Agios Pharmaceuticals Inc, the total compensation of Christopher Bowden at Agios Pharmaceuticals Inc is 3,227,210$. There are 1 executives at Agios Pharmaceuticals Inc getting paid more, with Jacqualyn Fouse having the highest compensation of 16,608,000$.
Christopher Bowden is 58, he's been the Chief Medical Officer of Agios Pharmaceuticals Inc since 2014. There are 13 older and 7 younger executives at Agios Pharmaceuticals Inc. The oldest executive at Agios Pharmaceuticals Inc is Dr. Tak Wah Mak, 75, who is the Co-Founder & Member of Scientific Advisory Board.
Christopher's mailing address filed with the SEC is C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 11 years, insiders at Agios Pharmaceuticals Inc have traded over 77,887,085$ worth of Agios Pharmaceuticals Inc stock and bought 3,229,562 units worth 154,554,190$ . The most active insiders traders include Kevin P Starr、Robert Nelsen、John Maraganore. On average, Agios Pharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of 765,588$. The most recent stock trade was executed by Rahul D. Ballal on 11 August 2024, trading 2,302 units of AGIO stock currently worth 102,002$.
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
Agios Pharmaceuticals Inc executives and other stock owners filed with the SEC include: